Briacell Therapeutics Corp has seen a slight decline in its stock price this week amidst notable developments in its clinical trials and manufacturing capabilities.
Briacell Therapeutics Corp (BCT.TO) has experienced a challenging week in the market, with its stock price dropping by 5.73% over the past week and closing at C$5.24 on Monday. Despite this downturn, the company has made significant strides in its operations, particularly regarding its pivotal Phase 3 trial and manufacturing arrangements.
Investor takeaway: Investors should weigh the implications of Briacell's recent news against its current stock performance. While the company is advancing its clinical trials and manufacturing capabilities, the stock has faced considerable volatility this year.
Advertisement
Get up to $2,000 cash back
Open and fund a new Qtrade account with promo code SPRING26. Offer ends July 31, 2026.
Briacell Therapeutics Corp
BCT.TO
BCT.TO
Briacell Therapeutics Corp
WealthAwesomeMarket cap
$45.76M
52W high
$20.40
52W low
$3.68
1W change
-5.73%
Beta
1.54
Analyst Price Targets
Based on analyst covering BCT
Wall Street analysts forecast BCT stock price to rise 280.2% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$20.00
+280.2% Upside
Current Price
C$5.26
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on BCT's historical volatility
30-Day Vol
60.5%
Annualized
90-Day Vol
87.4%
Annualized
Trend (90d)
-10.3%
Annualized drift
90d Mean
C$5.07
Expected price
| Horizon | Expected | 68% Range (1ฯ) |
|---|---|---|
| 30 trading days | C$5.20 | C$4.22 โ C$6.40 |
| 60 trading days | C$5.13 | C$3.82 โ C$6.89 |
| 90 trading days | C$5.07 | C$3.53 โ C$7.28 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ยฑ1ฯ, 95% band = ยฑ2ฯ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
C$5.24
Briacell's stock closed at C$5.24, reflecting a significant 38.6% decline from its 200-day moving average of C$8.54.
Bull case
The positive outlook for Briacell is supported by the recent opening of its first Canadian site for a pivotal Phase 3 trial in metastatic breast cancer, which could boost its market presence and investor confidence. Additionally, the partnership with FUJIFILM Biotechnologies for scalable manufacturing may help the company meet the potential demand for its therapies.
Bear case
On the flip side, the stock's performance has been disappointing in 2023, down nearly 46% year-to-date. The low trading volume compared to the 20-day average suggests limited investor interest, which could hinder future growth. Furthermore, the company's negative profit margin and return on equity raise concerns about its financial health.
Recent Company News
Briacell Therapeutics has made headlines this month with several key announcements. On July 16, the company opened its first Canadian site at Sunnybrook for a pivotal Phase 3 trial targeting metastatic breast cancer. This is a significant step in its clinical development strategy. Additionally, on July 15, Briacell arranged scalable manufacturing capabilities with FUJIFILM Biotechnologies, which may enhance its ability to produce its Bria-IMTโข therapy efficiently. Earlier, on July 7, the company engaged consulting and branding firms to support the commercial and market access evaluation of Bria-IMTโข, indicating its commitment to market readiness.
Technical Picture
Briacell's stock closed at C$5.24, which is 10.4% above its 50-day moving average of C$4.75 but 38.6% below its 200-day moving average of C$8.54. The stock has traded within a 52-week range of C$3.68 to C$20.40, indicating significant volatility. With a beta of 1.54, the stock is more volatile than the overall market. Notably, the latest trading volume was 150 shares, significantly below the 20-day average volume of 7,009 shares, reflecting reduced trading activity.
Market Performance Overview
In terms of market performance, Briacell Therapeutics has faced challenges this year, with a year-to-date decline of 46.44%. Despite a more favorable performance of +33.16% over the last month, the stock's recent weekly decline of 5.73% raises concerns for potential investors. Analysts remain optimistic, with an average target price of C$20.00, implying a potential upside of 281.7% from the current price. However, investors should be cautious given the company's negative profit margin and return on equity.
Advertisement
